A Phase 3 interventional study of Bicalutamide and Placebo in Non-Metastatic Prostate Cancer, sponsored by AstraZeneca. Completed at 130 sites in 16 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-10.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing bicalutamide in Prostatic Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. bicalutamide · Prostatic Neoplasms.
Among the 55 studies testing bicalutamide in Prostatic Neoplasms, this one is the 3rd largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 1995, is one of 21 in phase 3, and was the 26th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 55 studies testing bicalutamide in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Martin T. King, MD, PhD · Sites in United States
Ages 18+ · Men only
Marco Lorenzo Bonu · Sites in Italy
Ages 18–80 · Men only
Washington University School of Medicine · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
bicalutamide: first FDA approval 1995 (CASODEX). What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 21 · Phase 3 22 · Phase 4 5
First in 1994; this study’s year is marked. 3 started in 1995.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,588 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 53 across the 54 interventional studies. Of the 42 that completed or were terminated, 10 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 55 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
91 studies in Prostatic Neoplasms by AstraZeneca: 15 open now, 29 under way, 8 of them phase 3. Of 58 finished, 11 (19%) have results posted.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 2nd largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 1995, is one of 17 in phase 3, and was the 25th registered.
AstraZeneca’s Prostatic Neoplasms studies by the year they started, since 1994.
5 of the studies testing bicalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00223145Phase 3Abdenour NabidStudy on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone | 2026-12-31 |
| NCT07393867Martin T. King, MD, PhDAndrogen-responsive POSLUMA-guided Intra-prostatic Boost | 2026-12-15 |
| NCT07783282Astellas Pharma Global Development, Inc.A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | 2027-04-30 |
| NCT04025372Brigham and Women's HospitalINTREPId (INTermediate Risk Erection PreservatIon Trial) | 2027-10-01 |
| NCT07593079Washington University School of MedicineProstate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer | 2027-11-14 |
Add all 5 to your calendar (.ics) → With an account.
Among the 55 studies testing bicalutamide in Prostatic Neoplasms, from their registry updates:
Among AstraZeneca’s 91 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Bicalutamide
150mg p.o. daily
Also known as: Casodex
Time to clinical progression
Time frame: Throughout study period
Tolerability in terms of adverse events and laboratory parameters
Time frame: Throughout study period
Survival
Time frame: Throughout study period
Time to treatment failure
Time frame: Throughout study period
Prostate-specific antigen
Time frame: Initial study period up to 2005 amended protocol
Showing the first 100 of 130 sites across 16 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 1995, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bicalutamide